Page 1

November 12 , 2021 Xenetic BIOSCIENCES Xenetic Biosciences , Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update • Company advancing XCARTTM pre - clinical development plan toward IND- enabling studies • Strengthened cash position to fund operations through XCART IND filing with recently completed $ 12.5 million private placement • Continued royalty stream growth through license agreement with PolyXenⓇ platform technology FRAMINGHAM , MA / ACCESSWIRE / November 12 , 2021 Xenetic Biosciences , Inc. ( NASDAQ : XBIO ) ( " Xenetic " or the " Company " ) , a biopharmaceutical company focused on advancing XCART ™ , a personalized CAR T platform technology engineered to target patient- and tumor - specific neoantigens , today reported its financial results for the third quarter of 2021 and provided a corporate update . Xenetic BIOSCIENCES " Our team continues to advance the XCART program and validate key workflow and manufacturing components which move us closer to conducting IND - enabling studies . Building on the proven success of CAR T therapy , we believe that Xenetic's approach is innovative and is well - positioned to have a meaningful impact by addressing the significant unmet needs in certain hematological malignancies . As we continue to advance this important program and witness the potential of the XCART platform , our confidence holds strong in its ability to target cancers with a patient- and tumor - specific approach , " commented Jeffrey Eisenberg , Chief Executive Officer of Xenetic . XCART Platform Technology Overview : Significantly differentiated , proprietary approach to personalized CAR T lymphoma therapy targeting tumor - specific neoantigens that target independently of CD19 or other surface antigens that are common to both normal and malignant B - cells . Lead program for Non - Hodgkin lymphoma , an area of significant unmet need , with the potential to address an initial global market opportunity of over $ 7 billion annually.1 Program Highlights :